ACM
CSTL icon

AIGH Capital Management’s Castle Biosciences CSTL Stock Holding History

AIGH Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-545,101
Closed -$13M – 47
2026
Q2 		$13M Sell
545,101
-45,500
-8% -$1.01M 0.82% 22
2026
Q1 		$14.5M Sell
590,601
-34,118
-5% -$1.12M 1.98% 13
2025
Q4 		$24.3M Sell
624,719
-82,568
-12% -$2.66M 5.88% 3
2025
Q3 		$16.1M Buy
+707,287
New +$14.4M 4.54% 8

Other funds holding CSTL

Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Jefferies Financial Group
Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return
Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Kornitzer Capital Management
Kornitzer Capital Management Shawnee Mission, Kansas $4.8B AUM 30.14% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Perkins Capital Management
Perkins Capital Management Wayzata, Minnesota $140M AUM 109.55% 1-Year Est. Return

AIGH Capital Management's CSTL Position: Q3 2026 in Review

AIGH Capital Management sold out of Castle Biosciences (CSTL) in Q3 2026, closing a stake of 545,101 shares — an estimated $13M sold.

AIGH Capital Management first reported a position in CSTL in Q3 2025 and held it in 4 quarters. The position peaked at $24.3M in Q4 2025. 74 funds tracked by Wall St. Rank hold CSTL as of Q3 2026.

  • AIGH Capital Management reported no remaining Castle Biosciences position as of Q3 2026 after selling out during the quarter.
  • AIGH Capital Management sold 545,101 Castle Biosciences shares in Q3 2026, an estimated $13M.
  • AIGH Capital Management first reported a position in Castle Biosciences in Q3 2025 and held it in 4 quarters.
  • AIGH Capital Management's Castle Biosciences position peaked at $24.3M in Q4 2025.
  • 74 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2026.

Based on AIGH Capital Management's 13F filing for Q3 2026, filed 2 Nov 2026.